2.60 USD
▼-0.32-10.82%
盘后 2.63 +1.35%
2026-09-15
市值
$422.17M
市盈率
—
EPS
-1.54
股息率
—
52 周区间
1.82 – 4.23
成交量
7.24M
Beta
3.26
目标价
13.25
52W 低 1.8252W 高 4.23
价格走势
公司简介
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero...